Summary
A leading business intelligence provider, has released its latest research report, Non-Hodgkin
Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising
Pipeline Widen Targeted and Immunotherapeutic Treatment Options, which provides indepth insight into the indication. It provides estimates of market size for 2013 along with
forecasts until 2020 for the eight major developed markets, which comprises the US, UK,
France, Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology,
treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure
rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
The value of the NHL market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013
at a modest Compound Annual Growth Rate (CAGR) of 7.4%. The expected launch of promising
drugs, including novel small molecule inhibitors and next-generation monoclonal antibodies, as
well as the continued use of the current blockbuster, Rituxan/Mabthera (rituximab), will be the
key growth drivers. The launch of a premium-priced novel glycol-engineered antibody;
obinutuzumab; the personalized vaccine dasiprotimut-T, mTOR inhibitor everolimus, and
several kinase inhibitors including idelalisib and ibrutinib (which already gained FDA approval)
are expected to have a significant impact on the market size. Additionally, the extension of
indications of several already marketed drugs such as Revlimid as a maintenance therapy for
DLBCL, Velcade as a front-line therapy for MCL and Adcetris as front-line therapy for CD30 T-cell
lymphoma, will fuel the growth during the forecast period.
The emerging treatment challenges in the current treatment landscape (which include,
treatment of refractory/relapsed disease and increasing rituximab resistance) are expected to
be addressed by the promising NHL pipeline. In spite of a slew of expected approvals the
market is set to increase a modest pace due to the patent expiry of the gold-standard therapy
during the forecast period.
Scope
The report analyzes treatment usage patterns, market characterization, the pipeline, and key
licensing and co-development deals in the eight major developed markets of the US, UK,
France, Germany, Italy, Spain, Japan and Canada. It includes - A brief introduction to NHL, including the diseases pathogenesis, etiology, diagnosis and
treatment algorithms
- In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy,
treatment patterns and strengths/weaknesses and including a heat map that compares the
drugs in terms of safety and efficacy
- A comprehensive review of the pipeline for NHL, including individual analysis of a number of
late-stage pipeline drugs that are likely to enter the market during the forecast period; the
pipeline is analyzed on the basis of Phase distribution, molecule type, program type,
mechanism of action and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and
program failure rate for each molecule type
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
- Multi-scenario forecast data of the market to 2020, taking into account how the market may
be affected by the introduction of new drugs, the expiry of key patents on current drugs and
the changes in disease epidemiology across the key developed markets
Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the NHL
market since 2006
Reasons to buy
The report will enhance your decision-making capability by allowing you to - Understand the NHL pipeline and the factors that indicate that it is becoming more innovative
- Examine detailed profiles of promising pipeline products and gain an insight into how they are
likely to compete in the market and who their main competitors will be
- Follow the trends in NHL clinical trial size and duration in relation to industry averages and
assess the potential risk of future developmental programs according to mechanism of action
by considering the recorded clinical trial failure rates
- Observe the potential growth patterns expected for the NHL market over the forecast period,
identify which countries are expected to make the biggest contribution to this growth, and
devise a more effective country strategy through an understanding of key drivers and barriers
in the NHL market
- Accelerate and strengthen your market position by identifying key companies for strategic
partnerships
SWOT Analysis
Table of Content
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
2.1 Symptoms 10
2.2 Etiology 11
2.3 Pathophysiology 11
2.4 Diagnosis 12
2.4.1 Biopsy 12
2.4.2 Laboratory molecular tests 12
2.4.3 Imaging tests 13
2.5 Classification 13
2.5.1 B-Cell Lymphomas 14
2.5.2 T-Cell Lymphoma 16
2.6 Epidemiology 17
2.7 Prognosis and Disease Staging 18
2.7.1 Staging 19
2.8 Treatment Options 20
2.8.1 Surgery and Radiation Therapy 20
2.8.2 Stem Cell Transplantation 20
2.8.3 Pharmacological 21
2.8.4 Treatment Algorithms and Prescribing Habits 22
3 Marketed Products 25
3.1 Therapeutic Landscape 25
3.2 Targeted/Immunotherapies 25
3.2.1 Rituxan/Mabthera (rituximab) Roche 25
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
5.2.1 Drivers 70
5.2.2 Barriers 71
6 Deals and Strategic Consolidations 72
6.1 Major Co-development Deals 75
6.1.1 Roche Signs an Agreement with GlycArt and Genentech 76
6.1.2 Cell Therapeutics Enters Agreement with Bayer 76
6.1.3 Chugai Enters Co-development Agreement with Nippon Shinyaku for GA101 76
6.1.4 GlaxoSmithKline Enters Co-development Agreement with Genmab 76
6.1.5 Biogen Idec Enters Co-development Agreement with Genentech 76
6.1.6 Seattle Genetics Enters Co-development Agreement with Millennium 77
6.2 Major Licensing Deals 77
6.2.1 Spectrum Enters Licensing Agreement with Bayer for Zevalin 78
6.2.2 Janssen Biotech Enters Licensing Agreement with Pharmacyclics for PCI-32765 79
6.2.3 Lundbeck Enters Licensing Agreement with Cephalon 79
6.2.4 TG Therapeutics Enters Licensing Agreement with Ildong for Ublituximab 79
6.2.5 Provenance Enters Licensing Agreement with Merck Serono 79
6.2.6 Cephalon Enters Licensing Agreement with SymBio 79
6.2.7 Genentech Enters Licensing Agreement with Seattle Genetics 80
7 Appendix 81
7.1 Market Definitions 81
7.2 Abbreviations 81
7.3 Bibliography 84
7.4 Pipeline Tables 89
7.4.1 Discovery 89
7.4.2 Preclinical 90
7.4.3 Investigational New Drug-Filed 92
7.4.4 Phase I 93
7.4.5 Phase II 96
7.4.6 Phase III 99
7.5 Market Forecasts to 2020 101
7.5.1 Global 101
7.5.2 US 101
7.5.3 UK 102
7.5.4 France 102
7.5.5 Germany 103
7.5.6 Italy 103
7.5.7 Spain 104
7.5.8 Canada 104
7.5.9 Japan 105
Email ID- contact@jsbmarketresearch.com
Tel No- 91 2241236650
Published by- http:/www.jsbmarketresearch.com/
List Of Tables
Table 16: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Preclinical), 2014
90
Table 17: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (IND-filed), 2014 92
Table 18: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase I), 2014 93
Table 19: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase II), 2014 96
Table 20: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase III), 2014 99
Table 21: Non-Hodgkin Lymphoma Market, Global, Market Forecast, 20132020 101
Table 22: Non-Hodgkin Lymphoma Market, US, Market Forecast, 20132020 101
Table 23: Non-Hodgkin Lymphoma Market, UK, Market Forecast, 20132020 102
Table 24: Non-Hodgkin Lymphoma Market, Germany, Market Forecast, 20132020 102
Table 25: Non-Hodgkin Lymphoma Market, Germany, Market Forecast, 20132020 103
Table 26: Non-Hodgkin Lymphoma Market, Italy, Market Forecast, 20132020 103
Table 27: Non-Hodgkin Lymphoma Market, Spain, Market Forecast, 20132020 104
Table 28: Non-Hodgkin Lymphoma Market, Canada, Market Forecast, 20132020 104
Table 29: Non-Hodgkin Lymphoma Market, Japan, Market Forecast, 20132020 105
List Of Figures
Report Price:
Licence Type
Price
$ 4995
Site Licence
$ 9990
$ 14985
Related Reports:
Empty Capsules Market by Product (Hard gelatin, Non-gelatin capsules), Raw Material (Pig meat,
Bovine, HPMC), Therapeutic Application (Antibiotics, Vitamins) & by End User (Pharmaceutical, Health
Supplements) - Global Forecast to 2019
Market Digest: Multiparameter Patient Monitoring Devices 2006 to 2020 - Europe (Germany, France,
Italy, UK and Spain)
Global Cervical Cancer Diagnostic Tests Market 2014-2018
Empyema Global Clinical Trials Review, H2, 2014
Atelectasis Global Clinical Trials Review, H2, 2014
Bronchiolitis Obliterans Global Clinical Trials Review, H2, 2014
Chronic Asthma Global Clinical Trials Review, H2, 2014
Chronic Bronchitis Global Clinical Trials Review, H2, 2014
HIV-2 Infection Global Clinical Trials Review, H2, 2014
Hospital Acquired Pneumonia (HAP) Global Clinical Trials Review, H2, 2014
You can order this report by calling on +91 - 998 7295 242 or mail us
your contact details at contact@jsbmarketresearch.com
About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along
with providing in-depth analysis though reports, JSB market research also provides regular
updates of the market though newsletters. Our reports are a well-researched work of market
researchers with an extensive knowledge and a good level of market experience.